David Robbins

TL;DR: A phase 1 trial was performed to evaluate the safety and therapeutic potential of ex vivo modulation of a single UCB unit using dmPGE2 before reduced-intensity, double UCB transplantation, and demonstrated clear safety with durable, multilineage engraftment of dm PGE2-treated UCB units.

TL;DR: Results represent a proof of principal that targeted therapy with recombinant Fv-containing proteins can be clinically useful and LMB-2 may be an effective new therapy for patients with chemotherapy-resistant CD25(+) HCL.

TL;DR: iNK cells represent an “off-the-shelf” source of cells for immunotherapy with the capacity to target tumors and engage the adaptive arm of the immune system to make a “cold” tumor “hot” by promoting the influx of activated T cells to augment checkpoint inhibitor therapies.

TL;DR: In this paper, an initial screening of approximately 400 candidate genes by digital PCR in different fetal and adult tissues identified a subset of 24 gene markers specific for fetal nucleated RBC and trophoblasts, which were further evaluated and verified in more defined tissues and isolated cells through quantitative RT-PCR using custom Taqman probes specific for each gene.

TL;DR: In this paper, the authors provided improved methods for cell therapy in particular, the invention provides therapeutic compositions of enhanced hematopoietic stem and progenitor cells having improved engraftment and homing properties, and methods of making the therapeutic compositions.